Rein Therapeutics (NASDAQ:RNTX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports.
Separately, Weiss Ratings downgraded shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.
Check Out Our Latest Report on RNTX
Rein Therapeutics Stock Performance
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04. Equities research analysts forecast that Rein Therapeutics will post -0.47 earnings per share for the current year.
Institutional Trading of Rein Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Velan Capital Investment Management LP acquired a new stake in shares of Rein Therapeutics during the 2nd quarter worth approximately $1,768,000. Sequoia Financial Advisors LLC purchased a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $260,000. Marshall Wace LLP purchased a new position in shares of Rein Therapeutics during the 3rd quarter valued at approximately $127,000. Texas Capital Bank Wealth Management Services Inc lifted its stake in shares of Rein Therapeutics by 19.9% in the 3rd quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock valued at $290,000 after purchasing an additional 60,000 shares during the period. Finally, Rock Creek Group LLC lifted its stake in shares of Rein Therapeutics by 40.0% in the 3rd quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock valued at $141,000 after purchasing an additional 50,000 shares during the period. 90.89% of the stock is owned by institutional investors and hedge funds.
About Rein Therapeutics
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.
Further Reading
- Five stocks we like better than Rein Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
